[ad_1]
Researchers who study diabetic patients for over 50 years and who have never developed renal insufficiency have found higher rates of a certain group of enzymes involved in the metabolism of glucose, compared to those with diabetes who have developed kidney failure.
The study builds on the findings of a study conducted in 2017 by Joslin Medalist on protective factors and diabetic kidney failure (DKD). The medalists have been patients with diabetes for more than 50 years. The research team was led by Hetal Shah, Mre, MPH, badociate researcher at the Joslin Diabetes Center and the HMS Instructor in Medicine, along with Daniel Gordin, MD, doctorate Adjunct Professor at Joslin and Adjunct Professor at the University of Helsinki in Finland, and George King, MD, Joslin Senior Vice President and Scientific Leader and Professor HMS in Medicine.
Hetal Shah
Daniel Gordin
The fact that Joslin medalists have a low complication rate has puzzled researchers around the world, Gordin said.
"This has built the logic that there must be something that protects these people from diabetic nephropathy. This would explain how these people are able to live with insulin-dependent diabetes for so many years, "he said in a statement from the Joslin Diabetes Center.
Ssearch for protective factors
As part of the study, which enrolled 1,008 American patients with type 1 diabetes who have been well documented for more than 50 years, researchers undertook to examine the following three questions related to the discovery of 2017:
- Did PKM2 protect non-medalists or diabetic patients under the age of 50?
- Has PKM2 been circulated in the medalists' plasma or has it only been found in the kidneys? and
- Do the medalists have any other protective factors to explore?
"The hypothesis of this study was that the upregulation of PKM2 and glucose metabolism enzymes and the TCA cycle protecting the diabetic kidney as in people with type 1 diabetes of extreme duration (medalists ) could be replicated and expanded in two tissues, glomeruli and plasma, people with type 1 diabetes of shorter duration and type 2 diabetes, "the authors wrote. "Therefore, we sought to expand our previous findings on elevations of glomerular PKM2 and four other glycolytic enzymes in type 1 and type 2 diabetes.
"In addition, we sought to replicate the glomerular metabolomic and proteomic findings of medalists protected against chronic kidney disease by performing similar plasma badays in a larger sample of medalists and to discover new markers of renal protection through these studies. unbiased omics screens, "they wrote.
To answer the first question, the researchers studied post mortem kidneys given by patients from all the cohorts they wanted to investigate. For the second question, they used proteomic and metabolomic techniques to study the circulating plasma of Medalists. Finally, they examined the plasma and identified a number of metabolites and proteins also high. They mapped the badociated genetic pathways to understand the cause and effect of elevations.
"We have been able to replicate the high PKM2 results in type 1 and type 2 diabetics with good kidney function," Shah said in a statement. "In addition, thanks to proteomic and metabolomic plasma studies conducted in medalists, we discovered that there is an amyloid precursor protein, or APP, that appears as a potential protective factor against the disease. kidney failure related to diabetes. "
More studies needed
High levels of PPH were also badociated with an increased risk of Alzheimer's disease, the statement said.
"[But it also seems to be] potentially protective in many vulnerable tissues in people with diabetes. That said, we would need additional studies to confirm it, "said Shah.
Understanding the protective factors of DKD could have clinical implications. If a biomarker circulates in the blood, it could allow doctors to perform a simple blood test to determine the risk of developing DKD for a patient. They could then create custom intervention courses.
Once the protection mechanisms are explicitly defined, they could even be used as therapeutic targets, noted Joslin officials.
"Diabetic kidney disease is a devastating disease," said Gordin. "It's a powerful factor in cardiovascular disease and possibly mortality. We urgently need to find something to help these people. All [these studies] take time, but it is very promising. "
Reference:
www.joslin.org/joslin-news.html
Disclosure s : The National Institute of Diabetes, Digestive and Kidney Diseases, the Juvenile Diabetes Research Foundation, the Tom Beatson Jr 284 Foundation, and many individual medalists have funded the 50-year medal winners' study. This study was also funded by a basic research grant from Sanofi-Aventis Deutschland GmbH. Gordin was supported by the Mary K. Iacocca grant from the Iacocca Foundation and grants from the Wilhelm and Else Stockmann Foundation, the Finnish Medical Society (Finska Läkaresällskapet), the Finnish Medical Foundation and the Biomedicum Helsinki Foundation.
Researchers who study diabetic patients for over 50 years and who have never developed renal insufficiency have found higher rates of a certain group of enzymes involved in the metabolism of glucose, compared to those with diabetes who have developed kidney failure.
The study builds on the findings of a study conducted in 2017 by Joslin Medalist on protective factors and diabetic kidney failure (DKD). The medalists have been patients with diabetes for more than 50 years. The research team was led by Hetal Shah, Mre, MPH, badociate researcher at the Joslin Diabetes Center and the HMS Instructor in Medicine, along with Daniel Gordin, MD, doctorate Adjunct Professor at Joslin and Adjunct Professor at the University of Helsinki in Finland, and George King, MD, Joslin Senior Vice President and Scientific Leader and Professor HMS in Medicine.
Hetal Shah
Daniel Gordin
The fact that Joslin medalists have a low complication rate has puzzled researchers around the world, Gordin said.
"This has built the logic that there must be something that protects these people from diabetic nephropathy. This would explain how these people are able to live with insulin-dependent diabetes for so many years, "he said in a statement from the Joslin Diabetes Center.
Ssearch for protective factors
As part of the study, which enrolled 1,008 American patients with type 1 diabetes who have been well documented for more than 50 years, researchers undertook to examine the following three questions related to the discovery of 2017:
- Did PKM2 protect non-medalists or diabetic patients under the age of 50?
- Has PKM2 been circulated in the medalists' plasma or has it only been found in the kidneys? and
- Do the medalists have any other protective factors to explore?
"The hypothesis of this study was that the upregulation of PKM2 and glucose metabolism enzymes and the TCA cycle protecting the diabetic kidney as in people with type 1 diabetes of extreme duration (medalists ) could be replicated and expanded in two tissues, glomeruli and plasma, people with type 1 diabetes of shorter duration and type 2 diabetes, "the authors wrote. "Therefore, we sought to expand our previous findings on elevations of glomerular PKM2 and four other glycolytic enzymes in type 1 and type 2 diabetes.
"In addition, we sought to replicate the glomerular metabolomic and proteomic findings of medalists protected against chronic kidney disease by performing similar plasma badays in a larger sample of medalists and to discover new markers of renal protection through these studies. unbiased omics screens, "they wrote.
To answer the first question, the researchers studied post mortem kidneys given by patients from all the cohorts they wanted to investigate. For the second question, they used proteomic and metabolomic techniques to study the circulating plasma of Medalists. Finally, they examined the plasma and identified a number of metabolites and proteins also high. They mapped the badociated genetic pathways to understand the cause and effect of elevations.
"We have been able to replicate the high PKM2 results in type 1 and type 2 diabetics with good kidney function," Shah said in a statement. "In addition, thanks to proteomic and metabolomic plasma studies conducted in medalists, we discovered that there is an amyloid precursor protein, or APP, that appears as a potential protective factor against the disease. kidney failure related to diabetes. "
PAGE BREAK
More studies needed
High levels of PPH were also badociated with an increased risk of Alzheimer's disease, the statement said.
"[But it also seems to be] potentially protective in many vulnerable tissues in people with diabetes. That said, we would need additional studies to confirm it, "said Shah.
Understanding the protective factors of DKD could have clinical implications. If a biomarker circulates in the blood, it could allow doctors to perform a simple blood test to determine the risk of developing DKD for a patient. They could then create custom intervention courses.
Once the protection mechanisms are explicitly defined, they could even be used as therapeutic targets, noted Joslin officials.
"Diabetic kidney disease is a devastating disease," said Gordin. "It's a powerful factor in cardiovascular disease and possibly mortality. We urgently need to find something to help these people. All [these studies] take time, but it is very promising. "
Reference:
www.joslin.org/joslin-news.html
Disclosure s : The National Institute of Diabetes, Digestive and Kidney Diseases, the Juvenile Diabetes Research Foundation, the Tom Beatson Jr 284 Foundation, and many individual medalists have funded the 50-year medal winners' study. This study was also funded by a basic research grant from Sanofi-Aventis Deutschland GmbH. Gordin was supported by the Mary K. Iacocca grant from the Iacocca Foundation and grants from the Wilhelm and Else Stockmann Foundation, the Finnish Medical Society (Finska Läkaresällskapet), the Finnish Medical Foundation and the Biomedicum Helsinki Foundation.
[ad_2]
Source link
